SC
ZBIO

Steven Cohen’s Zenas BioPharma ZBIO Stock Holding History

Steven Cohen’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,500
Closed -$635K – 4658
2025
Q4 		$635K Buy
+17,500
New +$576K ﹤0.01% 3119

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Steven Cohen's ZBIO Position: Q2 2026 in Review

Steven Cohen opened a new position in Zenas BioPharma (ZBIO) in Q2 2026: 16,136 shares worth $410K. The stake represents ﹤0.01% of the portfolio and ranks #3263 among its holdings. This is a return to the name: Steven Cohen previously reported a position in ZBIO as recently as Q4 2025.

Steven Cohen first reported a position in ZBIO in Q3 2024 and has held it in 3 quarters since. The position peaked at $9.21M in Q4 2025. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Steven Cohen held 16,136 shares of Zenas BioPharma worth $410K as of Q2 2026.
  • Zenas BioPharma was a new Steven Cohen position in Q2 2026.
  • Zenas BioPharma made up ﹤0.01% of Steven Cohen's portfolio in Q2 2026, its #3263 holding.
  • Steven Cohen first reported a position in Zenas BioPharma in Q3 2024 and has held it in 3 quarters since.
  • Steven Cohen's Zenas BioPharma position peaked at $9.21M in Q4 2025.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.